Ser39
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser39  -  E2A (human)

Site Information
NGkGRPAsLAGAQFG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15500103

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PAK5 (human) ( 1 )
Kinases, in vitro:
PAK5 (human) ( 1 )
Treatments:
HGF ( 1 )

Downstream Regulation
Effects of modification on E2A:
intracellular localization ( 1 )
Effects of modification on biological processes:
cell adhesion, inhibited ( 1 ) , cell motility, induced ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal cancer ( 1 )

References 

1

Zhu G, et al. (2016) PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer. Oncogene 35, 1943-54
26212009   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info